SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Siga Technologies (SIGA) Stock Undervalued Right Now?

Gap Inc

Gray TV

Hims & Hers Health

BRFS, GPS, GTN, HIMS and SIGA have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2024.

New Strong Buy Stocks for May 8th

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Brian Adams - Carter, Terry Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

SIGA Technologies, Inc. (SIGA) Q1 2024 Earnings Call Transcript

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2024.

SIGA Reports Financial Results for Three Months Ended March 31, 2024

Siga Technologies (SIGA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Siga Technologies (SIGA) Upgraded to Strong Buy: Here's What You Should Know

Morgan Stanley

Netflix

Tenet Healthcare

Taylor Morrison Home

MS, NFLX, SIGA, THC and TMHC have been added to the Zacks Rank #1 (Strong Buy) List on May 3, 2023.

New Strong Buy Stocks for May 3rd

SIGA, TMHC and THC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 3, 2023.

Best Value Stocks to Buy for May 3rd

Siga Technologies Inc. (SIGA) closed the most recent trading day at $9.44, moving +1.34% from the previous trading session.

Siga Technologies Inc. (SIGA) Rises Higher Than Market: Key Facts

NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results

Northern Trust

SEI Investments

SIGA, SEIC and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 12, 2024.

Best Momentum Stocks to Buy for April 12th

Ameri Holdings

Intrusion

Zuora

ZUO, INTZ, SIGA, ENVB and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2024.

New Strong Buy Stocks for April 12th

SIGA and AZZ made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 12, 2024.

Best Value Stocks to Buy for April 12th

Adecoagro

Dell Technologies

DELL, AGRO and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 10, 2023.

Best Momentum Stocks to Buy for April 10th

StepStone Group

Weave Communications

DELL, WEAV, AGRO, SIGA and STEP have been added to the Zacks Rank #1 (Strong Buy) List on April 10, 2023.

New Strong Buy Stocks for April 10th

High Tide

Marathon Petroleum

HITI, MPC and SIGA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 2, 2023.

Best Momentum Stocks to Buy for April 2nd

Crescent Point Energy

Cytek Biosciences

Crexendo, Inc.

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

New Strong Buy Stocks for April 2nd

NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships.

SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®

SIGA stock is setting new 52-week highs after a strong earnings report. The post-earnings rally is also supported by a special cash dividend of $0.60, going ex-dividend on 25 March.

Siga Technologies: Preparing For A Contingency If Tomorrow Comes

Siga Technologies (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Siga Technologies (SIGA) Rating Upgrade to Buy

SIGA Technologies, Inc. (SIGA) Q4 2023 Earnings Call Transcript

• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product revenues and approximately $84 million of pre-tax operating income,” stated Diem Nguyen, Chief Executive Officer.

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company's common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023.

SIGA Declares Special Cash Dividend of $0.60 Per Share

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company's Board of Directors. SIGA's current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024.

SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer

SIGA Technologies delivered impressive net sales expectations for Q4 and is working to expand its treatment of human smallpox in new jurisdictions. The company has regulatory approvals for its oral antiviral drug Tpoxx and is exploring expanding its FDA label to include post-exposure prophylaxis against smallpox. SIGA stock has established significant agreements with government entities and international organizations to supply its Tpoxx product, which could drive net sales growth.

News for SIGA Technologies Stock (SIGA)